Oliver Luxxe Assets LLC Buys Shares of 12,303 Allergan plc (AGN)
Oliver Luxxe Assets LLC bought a new position in shares of Allergan plc (NYSE:AGN) during the first quarter, Holdings Channel reports. The firm bought 12,303 shares of the company’s stock, valued at approximately $2,939,000. Allergan plc accounts for about 2.0% of Oliver Luxxe Assets LLC’s investment portfolio, making the stock its 19th largest position.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Trust Co raised its position in Allergan plc by 0.7% in the fourth quarter. Trust Co now owns 1,214 shares of the company’s stock worth $255,000 after buying an additional 9 shares during the period. Apriem Advisors raised its position in Allergan plc by 1.2% in the third quarter. Apriem Advisors now owns 1,021 shares of the company’s stock worth $235,000 after buying an additional 12 shares during the period. High Point Bank & Trust Co. raised its position in Allergan plc by 3.6% in the third quarter. High Point Bank & Trust Co. now owns 717 shares of the company’s stock worth $165,000 after buying an additional 25 shares during the period. Mosaic Family Wealth LLC raised its position in Allergan plc by 2.3% in the third quarter. Mosaic Family Wealth LLC now owns 1,101 shares of the company’s stock worth $254,000 after buying an additional 25 shares during the period. Finally, Barrington Strategic Wealth Management Group LLC raised its position in Allergan plc by 0.9% in the fourth quarter. Barrington Strategic Wealth Management Group LLC now owns 2,905 shares of the company’s stock worth $610,000 after buying an additional 26 shares during the period. 86.40% of the stock is owned by hedge funds and other institutional investors.
Shares of Allergan plc (NYSE:AGN) traded down 1.16% during mid-day trading on Tuesday, hitting $233.38. 1,070,028 shares of the stock were exchanged. The company has a 50-day moving average price of $239.64 and a 200-day moving average price of $221.34. Allergan plc has a 12 month low of $184.50 and a 12 month high of $261.27. The stock has a market cap of $78.23 billion, a price-to-earnings ratio of 6.11 and a beta of 1.07.
Allergan plc (NYSE:AGN) last posted its quarterly earnings data on Wednesday, February 8th. The company reported $3.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.76 by $0.14. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. The firm earned $3.86 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same period in the prior year, the company earned $3.41 EPS. The firm’s revenue was up 7.1% compared to the same quarter last year. Equities analysts expect that Allergan plc will post $16.03 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Oliver Luxxe Assets LLC Buys Shares of 12,303 Allergan plc (AGN)” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at http://www.dailypolitical.com/2017/04/18/oliver-luxxe-assets-llc-buys-shares-of-12303-allergan-plc-agn.html.
A number of research analysts recently weighed in on the stock. Sanford C. Bernstein set a $275.00 target price on shares of Allergan plc and gave the company a “buy” rating in a report on Sunday, December 25th. Royal Bank of Canada set a $279.00 price objective on shares of Allergan plc and gave the stock a “buy” rating in a research note on Wednesday, April 12th. Vetr lowered shares of Allergan plc from a “hold” rating to a “sell” rating and set a $211.12 price objective for the company. in a research note on Thursday, January 5th. Deutsche Bank AG lifted their price objective on shares of Allergan plc from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Tuesday, March 28th. Finally, Goldman Sachs Group Inc lowered shares of Allergan plc from a “conviction-buy” rating to a “buy” rating in a research note on Wednesday, December 21st. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $267.65.
In related news, Director Paul Bisaro sold 70,000 shares of the stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $246.68, for a total value of $17,267,600.00. Following the completion of the transaction, the director now directly owns 274,226 shares of the company’s stock, valued at approximately $67,646,069.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.27% of the stock is currently owned by corporate insiders.
About Allergan plc
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.